Email updates

Keep up to date with the latest news and content from Lipids in Health and Disease and BioMed Central.

Open Access Highly Accessed Research

A randomized clinical trial to determine the efficacy of manufacturers’ recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction

Maggie Laidlaw*, Carla A Cockerline and William J Rowe

Author Affiliations

Nutrasource Diagnostic Inc., 120 Research Lane, University of Guelph Research Park, Suite 203, Guelph N1G0B4, Ontario, Canada

For all author emails, please log on.

Lipids in Health and Disease 2014, 13:99  doi:10.1186/1476-511X-13-99

Published: 21 June 2014

Abstract

Background

Omega-3 fatty acids confer beneficial health effects, but North Americans are lacking in their dietary omega-3-rich intake. Supplementation is an alternative to consumption of fish; however, not all omega-3 products are created equal. The trial objective was to compare the increases in blood levels of omega-3 fatty acids after consumption of four different omega-3 supplements, and to assess potential changes in cardiovascular disease risk following supplementation.

Methods

This was an open-label, randomized, cross-over study involving thirty-five healthy subjects. Supplements and daily doses (as recommended on product labels) were:

Concentrated Triglyceride (rTG) fish oil: EPA of 650 mg, DHA of 450 mg

Ethyl Ester (EE) fish oil: EPA of 756 mg, DHA of 228 mg

Phospholipid (PL) krill oil: EPA of 150 mg, DHA of 90 mg

Triglyceride (TG) salmon oil: EPA of 180 mg, DHA of 220 mg.

Subjects were randomly assigned to consume one of four products, in random order, for a 28-day period, followed by a 4-week washout period. Subsequent testing of the remaining three products, followed by 4-week washout periods, continued until each subject had consumed each of the products. Blood samples before and after supplementation were quantified for fatty acid analysis using gas chromatography, and statistically analysed using ANOVA for repeated measures.

Results

At the prescribed dosage, the statistical ranking of the four products in terms of increase in whole blood omega-3 fatty acid levels was concentrated rTG fish oil > EE fish oil > triglyceride TG salmon oil > PL krill oil. Whole blood EPA percentage increase in subjects consuming concentrated rTG fish oil was more than four times that of krill and salmon oil. Risk reduction in several elements of cardiovascular disease was achieved to a greater extent by the concentrated rTG fish oil than by any other supplement. Krill oil and (unconcentrated) triglyceride oil were relatively unsuccessful in this aspect of the study.

Conclusion

For the general population, the form and dose of omega-3 supplements may be immaterial. However, given these results, the form and dose may be important for those interested in reducing their risk of cardiovascular disease.

Trial registration

ClinicalTrials.gov: NCT01960660.

Keywords:
Omega-3 supplements; Cardiovascular disease; Risk biomarkers